MIFH
CCCC icon

Migdal Insurance & Financial Holdings’s C4 Therapeutics CCCC Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-605
Closed -$20K – 614
2021
Q4 		$20K Sell
605
-589
-49% -$23.3K ﹤0.01% 558
2021
Q3 		$53K Buy
+1,194
New +$51.1K ﹤0.01% 438

Other funds holding CCCC

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Migdal Insurance & Financial Holdings's CCCC Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of C4 Therapeutics (CCCC) in Q1 2022, closing a stake of 605 shares — an estimated $20K sold.

Migdal Insurance & Financial Holdings first reported a position in CCCC in Q3 2021 and held it in 2 quarters. The position peaked at $53K in Q3 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining C4 Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 605 C4 Therapeutics shares in Q1 2022, an estimated $20K.
  • Migdal Insurance & Financial Holdings first reported a position in C4 Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's C4 Therapeutics position peaked at $53K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.